Cargando…
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604
BACKGROUND: The role of irinotecan for elderly patients with LD-SCLC has been unclear, and the timing of TRT combined with chemotherapy has not been fully evaluated. METHODS: Patients aged > 70 years with untreated, measurable, LD-SCLC, performance status (PS) 0–2, and adequate organ function wer...
Autores principales: | Misumi, Yuki, Okamoto, Hiroaki, Sasaki, Jiichiro, Masuda, Noriyuki, Ishii, Mari, Shimokawa, Tsuneo, Hosomi, Yukio, Okuma, Yusuke, Nagamata, Makoto, Ogura, Takashi, Kato, Terufumi, Sata, Masafumi, Otani, Sakiko, Takakura, Akira, Minato, Koichi, Miura, Yosuke, Yokoyama, Takuma, Takata, Saori, Naoki, Katsuhiko, Watanabe, Koshiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446686/ https://www.ncbi.nlm.nih.gov/pubmed/28549414 http://dx.doi.org/10.1186/s12885-017-3353-y |
Ejemplares similares
-
Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913
por: Nakahara, Yoshiro, et al.
Publicado: (2020) -
Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014
por: Takagi, Yusuke, et al.
Publicado: (2015) -
Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426
por: Ichikawa, Yasuko, et al.
Publicado: (2023) -
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022) -
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
por: Ikeda, Satoshi, et al.
Publicado: (2018)